Researchers Find Functions of 2 Types of B Cells

A specialized subpopulation of the antibody-producing B cells of the immune system plays a "double-barreled" role in triggering both kinds of immunity -- innate and acquired, Duke University immunologists have discovered. The division of labor between B-1a and B-1b cells they have uncovered offers basic insights that could contribute to more rational development of vaccines.



B cells are the arms factories of the immune system, producing antibodies that target invading microbes for destruction. Generally, B-1 cells have been thought to play a major role in the innate immune response -- the type of immunity that offers rapid, generalized responses to infections. Less understood has been any role in adaptive immunity -- in which the immune system develops a long-term immune response to an invader after vaccination or infection.



The researchers concluded that the B-1a cells regulate the innate immune response and the B-1b cells regulate the adaptive, long-term immune response. Knowing this, researchers can work on finding a vaccine mechanism for diseases such as B cell lymphomas.

News Release

Blog Category: 

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap